
Pharmaceutical firm Lundbeck is arming itself for battle with several generic drugmakers wanting to produce generic versions of schizophrenia treatment Rexulti before its patent expires.
Alongside Japanese partner Otsuka, Lundbeck is prepping for court, where the patent brawl is set to start on July 25, 2022.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app